|
1
|
Pennathur A, Gibson MK, Jobe BA and
Luketich JD: Oesophageal carcinoma. Lancet. 381:400–412. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang Y: Epidemiology of esophageal
cancer. World J Gastroenterol. 19:5598–5606. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Enzinger PC and Mayer RJ: Esophageal
Cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Quint LE, Hepburn LM, Francis IR, Whyte RI
and Orringer MB: Incidence and distribution of distant metastases
from newly diagnosed esophageal carcinoma. Cancer. 76:1120–1125.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ilson DH: Esophageal cancer chemotherapy:
Recent advances. Gastrointest Cancer Res. 2:85–92. 2008.PubMed/NCBI
|
|
6
|
Greene FL, Page DL, Fleming ID, Fritz AG,
Balch CM, Haller DG and Morrow M: Esophagus. American Joint
Committee on Cancer (AJCC) Cancer Staging Manual (6th). Springer.
(New York, NY). 90–95. 2002.
|
|
7
|
Trotti A, Colevas AD, Setser A, Rusch V,
Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN and
Rubin P: CTCAE v3.0: Development of a comprehensive grading system
for the adverse effects of cancer treatment. Semin Radiat Oncol.
13:176–181. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Iizuka T, Kakegawa T, Ide H, Ando N,
Watanabe H, Tanaka O, Takagi I, Isono K, Ishida K, Arimori M, et
al: Phase II evaluation of cisplatin and 5-fluorouracil in advanced
squamous cell carcinoma of the esophagus: A Japanese esophageal
oncology group trial. Jpn J Clin Oncol. 22:172–176. 1992.PubMed/NCBI
|
|
9
|
The National Comprehensive Cancer Network
(NCCN) Guidelines Version 1.2014: Esophageal and Esophagogastric
Junction Cancers. http://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdfAccessed.
March 01–2015
|
|
10
|
Cunningham D, Okines AF and Ashley S:
Capecitabine and oxaliplatin for advanced esophagogastric cancer. N
Engl J Med. 362:858–859. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shirasaka T, Shimamato Y, Ohshimo H,
Yamaguchi M, Kato T, Yonekura K and Fukushima M: Development of a
novel form of an oral 5-fluorouracil derivative (S-1) directed to
the potentiation of the tumor selective cytotoxicity of
5-fluorouracil by two biochemical modulators. Anticancer Drugs.
7:548–557. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Akutsu Y, Kono T, Uesato M, Hoshino I,
Narushima K, Hanaoka T, Tochigi T, Semba Y, Qin W and Matsubara H:
S-1 monotherapy as second- or third-line chemotherapy for
unresectable and recurrent esophageal squamous cell carcinoma.
Oncology. 84:305–310. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Koizumi W, Narahara H, Hara T, Takagane A,
Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama
W, et al: S-1 plus cisplatin versus S-1 alone for first-line
treatment of advanced gastric cancer (SPIRITS trial): A phase III
trial. Lancet Oncol. 9:215–221. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hiraki M, Yunotani S, Noguchi R, Shinozaki
Y, Tani H, Sakai M, Ishimitsu T and Tabuchi M: Recurrence of
esophageal cancer treated by combination TS-1/CDDP therapy. Gan To
Kagaku Ryoho. 32:219–221. 2005.(In Japanese). PubMed/NCBI
|
|
15
|
Kanamori N, Fujii M, Takahashi T,
Wakabayashi K, Kochi M, Sou K and Takayama T: A patient with
esophageal cancer recurrence responding to S-1 combined with
cisplatin (CDDP). Gan To Kagaku Ryoho. 34:1459–1461. 2007.(In
Japanese). PubMed/NCBI
|
|
16
|
Kubota K, Mafune K, Yamada K, Yamashita H,
Kuroda J, Aikou S and Kaminishi M: Complete regression of advanced
esophageal cancer with abdominal bulky lymph node metastasis
treated by concurrent chemoradiotherapy using docetaxel, cisplatin
and 5-fluorouracil. Esophagus. 6:183–187. 2009. View Article : Google Scholar
|
